Unlock personalized cancer care. Book a Test Now
This is to bring to your notice that SOT Therapy from RGCC is not available in Singapore
Clavic-Q-RE
In the evolving landscape of cancer care, immunotherapy is changing cancer treatment forever. We’re proud to offer Clavic-Q-RE, a groundbreaking cancer immunotherapy treatment that harnesses the innate power of a patient’s own immune system to fight cancer. This autologous approach to personalized cancer care represents the next generation of precision medicine, offering hope to patients seeking alternatives beyond traditional chemotherapy and radiation.
This therapy available to various countries (excluding Singapore).
Clavic-Q-RE stands as a pioneering immunotherapy treatment for cancer that is a minimally manipulated cellular therapy also known as Autologous Adoptive Cellular Therapy. This innovative therapy is a significant advancement in personalized cancer care, offering patients a targeted approach that works with their body’s natural defense mechanisms.
The mechanism of action behind Clavic-Q-RE demonstrates why immunotherapy in cancer treatment has become such a promising field. The therapy works through multiple complementary pathways to identify, target, and eliminate cancer cells throughout the body.
Macrophages serve as the body’s primary cleanup crew, using their phagocytic capabilities to engulf and digest cancer cells and cellular debris. These versatile immune cells can recognize and eliminate cancer cells in an MHC-independent manner, meaning they don’t need specific antigen presentation to identify threats.
Natural Killer (NK) cells function as the immune system’s rapid response team, capable of immediately recognizing and destroying cancer cells without prior sensitization. They work by detecting abnormal protein expressions on cancer cell surfaces and releasing cytotoxic granules that induce cancer cell death.
The adaptive immune response is orchestrated through dendritic cells. In Clavic-Q-RE, the dendritic cells are already activated in vivo against tumor peptides that are recognized by MHC-II or MHC-I and expressed in the patient’s sample, creating a personalized vaccine effect.
These activated dendritic cells then educate cytotoxic T lymphocytes (CTLs) to recognize and target your specific cancer cells. Once activated, these CTLs circulate throughout the body with the ability to identify and eliminate cancer cells that express the targeted antigens, providing long-lasting, memory-based immunity.
Plasma cells in the therapy have been activated in vivo against specific tumor antigens expressed in the patient’s sample. These antibodies act as molecular “tags,” marking cancer cells for destruction by other immune components. This tagging system helps coordinate the immune response and ensures that cancer cells cannot hide from immune surveillance, making it an important tool for immunotherapy in cancer treatment.
Clavic-Q-RE is administered as three carefully timed doses, each containing both innate and adaptive immune cells. This staged approach allows for:
The therapy timeline spans four weeks, with doses administered every two weeks, allowing the immune system to build upon each treatment while maintaining therapeutic momentum.
Reserve your 15-minute free one on one discussion
Personalized Approach: Every dose is created specifically from your immune cells and targeted to your cancer antigens, ensuring maximum compatibility and effectiveness.
Comprehensive Immune Response: Unlike single-target therapies, Clavic-Q-RE activates multiple immune pathways, creating a robust, multi-faceted attack against cancer cells.
Excellent Safety Profile: As an autologous therapy, the risk of severe adverse reactions is minimized while therapeutic benefits are maximized.
Proven Science: Backed by peer-reviewed research and developed by RGCC's team of internationally recognized scientists and researchers.
Oncotrail has undergone rigorous evaluation to ensure high sensitivity and specificity, making it an invaluable tool for diagnostic purposes.
Through high-precision techniques, the test is used to monitor the effectiveness of a particular cancer treatment. This would objectively provide information on how well the treatment is going.
The non-invasive tracking of the cancer status would notify a treating physician whether to adjust current management or stay the course. This would be important to know in almost real-time rather than to find out much later that a treatment doesn't apply to a particular person.
A patient-centric revolution in cancer testing and monitoring. We are devoted to providing personalized tests designed with each patient’s unique genetic profile in mind.
RGCC Global Ltd
Suite 1701-02, 17/F, FWD Financial Centre, 308 Des Voeux Road Central, Hong Kong
202312501N
+852 7028 5202
IAS Accreditation Testing Laboratory
ISO 22000: 2018
Nr.: 20101200002689
ISO 22716: 2007
Nr.: 20019220006394
College of American Pathologists
Certificate of Accreditation
CAP#: 9239089
CLIA#: 99D2283882
Accreditation Certificate of Foreign Cell Processor
– Japanese Government
IAS Accreditation Medical Laboratory
ISO 45001: 2018
Nr.: 20152220006395
CLIA ID Number 99D2283882
Certificate of GMP Compliance
No. 512863-102689104
Production License for Investigational ATMPs for Human Use
Ref. No. 7282
©2025 Copy Right
